Panelists discuss how clinical trial data support the consistent efficacy of oral selective estrogen receptor degraders (SERDs) across diverse metastatic breast cancer subgroups—including patients with visceral disease, HER2-low tumors, or co-mutations such as PIK3CA—reinforcing the drug’s versatility and value as a treatment option beyond narrowly defined molecular profiles.
Panelists discuss the evolving management of estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer, highlighting the clinical impact of oral selective estrogen receptor degraders (SERDs)—particularly in patients with ESR1 mutations—while emphasizing the importance of biomarker-guided therapy selection and ongoing reassessment to optimize outcomes in the context of prior endocrine and CDK4/6 inhibitor exposure.
An expert discusses how the PEACE III trial demonstrated that combining radium-223 with enzalutamide significantly improved radiographic progression-free survival and overall survival compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who had bone metastases and limited prior treatment exposure.
An expert explains that metastatic castration-resistant prostate cancer (mCRPC) treatment is guided by prior therapies, disease features, and genetic profiles—favoring androgen receptor pathway inhibitors (ARPIs) for those without progression, PARP inhibitor combinations for patients with BRCA-mutated disease, and tailored options such as radium-223 for bone metastases or chemotherapy for aggressive, genetically altered tumors—with evolving strategies including radioligand therapies aimed at improving survival while preserving quality of life.
Panelists discuss how interferon therapy (particularly ropeginterferon) can provide better hematologic control over time and potentially modify disease progression in polycythemia vera patients.
Panelists discuss how to approach a 67-year-old man with advanced polycythemia vera who is resistant to hydroxyurea, requiring frequent phlebotomies despite maximum tolerated dosing, and experiencing new symptoms like night sweats and fatigue.
Panelists discuss how diagnosis and staging of anal cancer involves digital rectal examination, high-resolution anoscopy with biopsy, p16 testing, and pelvic MRI for accurate staging, while considering patient factors like HIV status, treatment adherence capability, and comorbidities when planning curative intent therapy.
Panelists discuss how anal cancer epidemiology shows increasing incidence in both sexes with HPV infection as the primary risk factor, affecting predominantly women with a median age of 60, while emphasizing the need to dispel misconceptions linking HPV-related anal cancer to sexual practices.
A panelist discusses how patients with advanced cGVHD often cycle through multiple approved agents over time due to plateauing responses, and describes upcoming clinical trials testing upfront use of these novel agents with corticosteroids in newly diagnosed patients to potentially improve outcomes.
An expert emphasizes that treatment decisions for metastatic castration-resistant prostate cancer (mCRPC) are highly personalized, balancing clinical efficacy with patient lifestyle, quality of life, and preferences—prioritizing overall survival alongside minimizing adverse effects and hospital visits—while endorsing flexible treatment durations, including breaks and dose adjustments, to maintain both effectiveness and patient well-being through shared decision-making.
An expert highlights that safety considerations in metastatic castration-resistant prostate cancer (mCRPC) treatment depend on prior therapies and disease status, emphasizing early combination therapy for better control, vigilant bone health management with bone-modifying agents, proactive adverse effect mitigation, and the importance of exercise, nutrition, and cardiovascular monitoring to optimize patient outcomes and quality of life.
Panelists discuss how to monitor patients on JAK inhibitors, including blood count checks every 1 to 2 weeks initially, baseline spleen imaging with follow-up at 3 to 6 months, and symptom burden assessment.
Panelists discuss how to select among the four available JAK inhibitors (Ruxolitinib, Fedratinib, Pacritinib, and Momelotinib) based on patient-specific factors such as anemia, thrombocytopenia, and symptom burden.
A panelist discusses how real-world experience with ruxolitinib and belumosidil shows similar response rates to clinical trials (45% and 65% respectively), emphasizes the importance of antimicrobial prophylaxis and supportive care, and describes gradual steroid tapering strategies once patients achieve responses.
An expert emphasizes that genomic profiling—including both germline and somatic testing—is now essential in metastatic prostate cancer management because it identifies key mutations such as homologous recombination repair (HRR) gene alterations that guide targeted therapies such as PARP inhibitors, informs the use of immune checkpoint inhibitors in select cases, and helps predict disease aggressiveness to tailor monitoring and treatment strategies.
An expert discusses recent trial data showing that combining radium-223 with enzalutamide modestly improves outcomes in metastatic castration-resistant prostate cancer (mCRPC) with bone metastases—highlighting the necessity of bone-modifying agents to reduce fracture risk—while results from the TRITON3 trial underscore the greater efficacy of PARP inhibitors such as rucaparib when used early and in combination for BRCA-mutated patients.
Panelists discuss how JAK inhibitor therapy can benefit patients with intermediate-1–risk myelofibrosis despite being studied primarily in higher-risk patients in the COMFORT and JUMP trials.
Panelists discuss how risk stratification, symptom burden, and splenomegaly guide treatment decisions for a 68-year-old woman with intermediate-risk myelofibrosis who isn’t interested in transplant.
A panelist discusses how to sequence the four approved cGVHD agents based on patient-specific factors, recommending axatilimab or belumosidil for lung involvement, any of the three oral agents for skin/joint disease, and ibrutinib for lymphoma patients, while considering individual toxicity profiles and disease manifestations.
An expert discusses how combining androgen receptor pathway inhibitors (ARPIs) with PARP inhibitors, particularly enzalutamide with talazoparib, has significantly improved outcomes in metastatic castration-resistant prostate cancer (mCRPC)—especially for patients with homologous recombination repair (HRR) mutations—underscoring the importance of early genomic testing and personalized combination therapy.
An expert discusses how treatment decisions in metastatic castration-resistant prostate cancer (mCRPC) increasingly depend on prior androgen receptor pathway inhibitor (ARPI) exposure, highlighting the need for individualized therapy sequencing based on evolving practice patterns and patient history.
Panelists discuss how future directions in chronic graft-vs-host disease (cGVHD) management may include preemptive use of targeted therapies, first-line treatment with newer agents, and cell-based approaches.
Panelists discuss how axatilimab demonstrates particularly good responses for gastrointestinal graft-vs-host disease (GVHD) and may improve sclerotic skin changes despite lower rates of overall skin response.
Panelists discuss how axatilimab showed promising response rates in the AGAVE-201 trial, even in patients with graft-vs-host disease (cGVHD) who had failed other approved therapies.
An expert shares clinical pearls with the community, offering insights and tips for managing patients effectively.
An expert discusses the safety profiles of combination regimens, effective strategies for managing side effects, and how to weigh the potential for toxicity versus efficacy/benefits when discussing treatment options with patients.
An expert discusses a treatment approach for the patient case above, how factors like brain metastases influence first-line treatment choices, reviews high-risk/CNS outcomes data from MARIPOSA and FLAURA2, and shares their impression of icPFS and DoR from MARIPOSA, along with how to determine which patients are best suited for either combination treatment option.
An expert discusses treatment goals for patients with EGFR-mutated advanced/metastatic NSCLC, how to approach combination therapy with high-risk patients, and how recent data has influenced their practice.
An expert discusses recent updates on first-line treatments in EGFR-mutated NSCLC, including the MARIPOSA trial comparing amivantamab + lazertinib vs osimertinib, and the FLAURA2 trial of osimertinib + chemotherapy, and how the data is likely to impact the treatment landscape.
An expert discusses the case of a 55-year-old man with EGFR-mutated advanced/metastatic NSCLC, focusing on treatment considerations and management strategies.